

Akzo Nobel reconfirms listing of Organon BioSciences

Arnhem, the Netherlands, January 25, 2007 — Akzo Nobel has previously announced its intention to separate its Pharma business, preferably through a listing of approximately 20 to 30 percent of Organon BioSciences shares on Euronext in Amsterdam in early 2007.

Over the last few weeks, Akzo Nobel has received preliminary expressions of interest from a number of parties regarding an acquisition of Organon BioSciences.

Akzo Nobel has carefully reviewed these preliminary proposals from the perspective of long-term shareholder value creation. Taking into consideration the interests of all stakeholders, the company reconfirms that it remains committed to its preferred route of a separate listing of Organon BioSciences.

As a result, Akzo Nobel has decided not to divert any resources away from pursuing the listing of Organon BioSciences within the original timeline.

- - -

Note for the editor

Akzo Nobel is a Global Fortune 500 company and is listed on both the Euronext Amsterdam and NASDAQ stock exchanges. It is also included on the Dow Jones Sustainability Indexes and FTSE4Good Index. Based in the Netherlands, we are a multicultural organization serving customers throughout the world with human and animal healthcare products, coatings, and chemicals. We employ more than 62,000 people and conduct our activities in four segments – human and animal health, coatings and chemicals – subdivided into 13 business units, with operating subsidiaries in more than 80 countries. Consolidated revenues for 2005 totaled EUR 13.0 billion. The financial results for 2006 will be published on February 15, 2007.

Internet: www.akzonobel.com

Not for publication – for more information

Akzo Nobel nv
Corporate Media Relations, tel. +31 26 366 43 43
Contact: Tim van der Zanden

Statements related to the Proposed Separation

This document does not constitute an offer of securities for sale in the United States of America or in any other jurisdiction in which such offer or solicitation is not authorized or to any person to whom it is unlawful to make such offer or solicitation. Securities may not be offered or sold in the United States absent registration or an exemption from registration under the U.S. Securities Act of 1933, as amended.

Neither Organon Biosciences N.V. nor Akzo Nobel N.V. intends to register any portion of the offering in the United States or conduct a public offering of shares of Organon Biosciences N.V. in the United States.

This announcement is not an offer to sell or a solicitation of an offer to buy the ordinary shares of Organon Biosciences N.V. in the Netherlands. Any offer to acquire such securities will be made, and any investor should make his investment decision, solely on the basis of the information contained in the prospectus to be made generally available in the Netherlands in connection with the proposed offering.

Safe Harbor Statement*

This press release may contain statements which address such key issues as Akzo Nobel's growth strategy, future financial results, market positions, product development, pharmaceutical products in the pipeline, and product approvals. Such statements should be carefully considered, and it should be understood that many factors could cause forecasted and actual results to differ from these statements. These factors include, but are not limited to, price fluctuations, currency fluctuations, progress of drug development, clinical testing and regulatory approval, developments in raw material and personnel costs, pensions, physical and environmental risks, legal issues, and legislative, fiscal, and other regulatory measures. Stated competitive positions are based on management estimates supported by information provided by specialized external agencies. For a more comprehensive discussion of the risk factors affecting our business please see our Annual Report on Form 20-F filed with the United States Securities and Exchange Commission, a copy of which can be found on the company's corporate website www.akzonobel.com.

* Pursuant to the U.S. Private Securities Litigation Reform Act 1995.